Novel biomarkers for the prediction of metastasis in colorectal cancer

Expert Opinion on Medical Diagnostics

Volumn 7, Issue 2, 2013, Pages 137-146

  Zlobec, Inti ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Biomarkers; Colorectal cancer; MACC1; Metastasis; RKIP; Tumor budding

Indexed keywords

METASTASIS ASSOCIATED IN COLON CANCER 1 PROTEIN; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CELL BUDDING; COLORECTAL CANCER; DISEASE MARKER; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; MICROSATELLITE INSTABILITY; PREDICTIVE VALUE; PROTEIN EXPRESSION; REVIEW; TUMOR BUDDING; COLORECTAL TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS;

COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84874323677     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2013.753054     Document Type: Review

References (99)

1. Keller ET, Fu Z, Brennan M. The biology of a prostate cancer metastasis suppressor protein: raf kinase inhibitor protein. J Cell Biochem 2005;94:273-8
2. Glimelius B, Cavalli-Bjorkman N. Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach-present status. Scand J Gastroenterol 2012;47:296-314
3. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4
4. Muto T, Mochizuki H, Masaki T. editors. Tumor budding in colorectal cancer. Nova Science Publishers, Inc., New York; 2006
5. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009;28:151-66
6. Masaki T, Matsuoka H, Sugiyama M, et al. Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer 2001;84:1317-21
7. Masaki T, Matsuoka H, Sugiyama M, et al. Laminin-5 gamma 2 chain and matrix metalloproteinase-2 may trigger colorectal carcinoma invasiveness through formation of budding tumor cells. Anticancer Res 2003;23:4113-19
8. Zlobec I, Lugli A, Baker K, et al. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer. J Pathol 2007;212:260-8
9. Jass JR, Barker M, Fraser L, et al. APC mutation and tumour budding in colorectal cancer. J Clin Pathol 2003;56:69-73
10. Tan EJ, Thuault S, Caja L, et al. Regulation of transcription factor Twist expression by the DNA architectural protein high mobility group A2 during epithelial-to-mesenchymal transition. J Biol Chem 2012;287:7134-45
11. Yusra, Semba S, Yokozaki H. Biological significance of tumor budding at the invasive front of human colorectal carcinoma cells. Int J Oncol 2012;41:201-10
12. Guzinska-Ustymowicz K. MMP-9 and cathepsin B expression in tumor budding as an indicator of a more aggressive phenotype of colorectal cancer (CRC). Anticancer Res 2006;26:1589-94
13. Guzinska-Ustymowicz K, Zalewski B, Kasacka I, et al. Activity of cathepsin B and D in colorectal cancer: relationships with tumour budding. Anticancer Res 2004;24:2847-51
14. Masaki T, Goto A, Sugiyama M, et al. Possible contribution of CD44 variant 6 and nuclear beta-catenin expression to the formation of budding tumor cells in patients with T1 colorectal carcinoma. Cancer 2001;92:2539-46
15. Portyanko A, Kovalev P, Gorgun J, Cherstvoy E. Beta(III)-tubulin at the invasive margin of colorectal cancer: possible link to invasion. Virchows Arch 2009;454:541-8
16. Toyoda A, Kawana H, Azuhata K, et al. Aberrant expression of human ortholog of mammalian enabled (hMena) in human colorectal carcinomas: implications for its role in tumor progression. Int J Oncol 2009;34:53-60
17. Shinto E, Jass JR, Tsuda H, et al. Differential prognostic significance of morphologic invasive markers in colorectal cancer: tumor budding and cytoplasmic podia. Dis Colon Rectum 2006;49:1422-30
18. Shinto E, Mochizuki H, Ueno H, et al. A novel classification of tumour budding in colorectal cancer based on the presence of cytoplasmic pseudo-fragments around budding foci. Histopathology 2005;47:25-31
19. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010;1:651-61
20. Hostettler L, Zlobec I, Terracciano L, Lugli A. ABCG5-positivity in tumor buds is an indicator of poor prognosis in node-negative colorectal cancer patients. World J Gastroenterol 2010;16:732-9
21. Betge J, Kornprat P, Pollheimer MJ, et al. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal Cancer. Ann Surg Oncol 2012;19(12):3706-12
22. Hase K, Shatney C, Johnson D, et al. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum 1993;36:627-35
23. Losi L, Ponti G, Gregorio CD, et al. Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma. Pathol Res Pract 2006;202:663-70
24. Lugli A, Karamitopoulou E, Panayiotides I, et al. CD8+ lymphocytes/tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer. Br J Cancer 2009;101:1382-92
25. Lugli A, Vlajnic T, Giger O, et al. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients. Hum Pathol 2011;42:1833-40
26. Nakamura T, Mitomi H, Kanazawa H, et al. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum 2008;51:568-72
27. Nakamura T, Mitomi H, Kikuchi S, et al. Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer. Hepatogastroenterology 2005;52:1432-5
28. Ohtsuki K, Koyama F, Tamura T, et al. Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res 2008;28:1831-6
29. Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to select high-risk patients in stage II well-differentiated or moderately differentiated colon adenocarcinoma. Dis Colon Rectum 2003;46:1400-6
30. Okuyama T, Oya M, Ishikawa H. Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinoma. Dis Colon Rectum 2002;45:628-34
31. Park KJ, Choi HJ, Roh MS, et al. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum 2005;48:1597-602
32. Syk E, Lenander C, Nilsson PJ, et al. Tumour budding correlates with local recurrence of rectal cancer. Colorectal Dis 2011;13:255-62
33. Tanaka M, Hashiguchi Y, Ueno H, et al. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum 2003;46:1054-9
34. Ueno H, Mochizuki H, Hashiguchi Y, et al. Predictors of extrahepatic recurrence after resection of colorectal liver metastases. Br J Surg 2004;91:327-33
35. Ueno H, Murphy J, Jass JR, et al. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002;40:127-32
36. Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol 2009;33:134-41
37. Morodomi T, Isomoto H, Shirouzu K, et al. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 1989;63:539-43
38. Glasgow SC, Bleier JI, Burgart LJ, et al. Meta-analysis of histopathological features of primary colorectal cancers that predict lymph node metastases. J Gastrointest Surg 2012;16(5):1019-28
39. Prall F, Nizze H, Barten M. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology 2005;47:17-24
40. Giger O, Comtesse S, Lugli A, et al. Intra-tumoral budding (ITB) in pre-operative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. Mod Pathol 2012;25(7):1048-53
41. Homma Y, Hamano T, Otsuki Y, et al. Severe tumor budding is a risk factor for lateral lymph node metastasis in early rectal cancers. J Surg Oncol 2010;102:230-4
42. Ishikawa Y, Akishima-Fukasawa Y, Ito K, et al. Histopathologic determinants of regional lymph node metastasis in early colorectal cancer. Cancer 2008;112:924-33
43. Kaneko I, Tanaka S, Oka S, et al. Immunohistochemical molecular markers as predictors of curability of endoscopically resected submucosal colorectal cancer. World J Gastroenterol 2007;13:3829-35
44. Kazama S, Watanabe T, Ajioka Y, et al. Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2. Br J Cancer 2006;94:293-8
45. Masaki T, Matsuoka H, Sugiyama M, et al. Budding as a useful determinant of the optimal treatment for T1 rectal carcinomas. Hepatogastroenterology 2003;50:388-91
46. Masaki T, Matsuoka H, Sugiyama M, et al. Actual number of tumor budding as a new tool for the individualization of treatment of T1 colorectal carcinomas. J Gastroenterol Hepatol 2006;21:1115-21
47. Nakadoi K, Tanaka S, Kanao H, et al. Management of T1 colorectal carcinoma with special reference to criteria for curative endoscopic resection. J Gastroenterol Hepatol 2012;27:1057-62
48. Suh JH, Han KS, Kim BC, et al. Predictors for lymph node metastasis in T1 colorectal cancer. Endoscopy 2012;44:590-5
49. Tateishi Y, Nakanishi Y, Taniguchi H, et al. Pathological prognostic factors predicting lymph node metastasis in submucosal invasive (T1) colorectal carcinoma. Mod Pathol 2010;23:1068-72
50. Yasuda K, Inomata M, Shiromizu A, et al. Risk factors for occult lymph node metastasis of colorectal cancer invading the submucosa and indications for endoscopic mucosal resection. Dis Colon Rectum 2007;50:1370-6
51. Horcic M, Koelzer V, Karamitopoulou E, et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol 2012; In press
52. Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007;50:151-62
53. Puppa G, Senore C, Sheahan K, et al. Diagnostic reproducibility of tumour budding in colorectal cancer: a multicentre, multinational study using virtual microscopy. Histopathology 2012; [Epub ahead of print]
54. Bernier I, Jolles P. Purification and characterization of a basic 23 kDa cytosolic protein from bovine brain. Biochim Biophys Acta 1984;790:174-81 . First report on RKIP.
55. Yeung K, Seitz T, Li S, et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 1999;401:173-7
56. Bevilacqua E, Frankenberger CA, Rosner MR. RKIP Suppresses Breast Cancer Metastasis to the Bone by Regulating Stroma-Associated Genes. Int J Breast Cancer 2012;2012:124704
57. Minn AJ, Bevilacqua E, Yun J, Rosner MR. Identification of novel metastasis suppressor signaling pathways for breast cancer. Cell Cycle 2012;11(13):2452-7
58. Li HZ, Gao Y, Zhao XL, et al. Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res 2009;7:832-40
59. Valadao M, Braggio D, Santos AF, et al. Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients. J Surg Res 2012;178(1):288-93
60. Fujimori Y, Inokuchi M, Takagi Y, et al. Prognostic value of RKIP and p-ERK in gastric cancer. J Exp Clin Cancer Res 2012;31:30
61. Jia B, Liu H, Kong Q, Li B. RKIP expression associated with gastric cancer cell invasion and metastasis. Tumour Biol 2012;33(4):919-25
62. Moen EL, Wen S, Anwar T, et al. Regulation of RKIP Function by Helicobacter pylori in Gastric Cancer. PLoS One 2012;7:e37819
63. Martinho O, Granja S, Jaraquemada T, et al. Downregulation of RKIP is associated with poor outcome and malignant progression in gliomas. PLoS One 2012;7:e30769
64. Zebisch A, Wolfler A, Fried I, et al. Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia. Leukemia 2012;26(8):1842-9
65. Birner P, Jesch B, Schultheis A, Schoppmann SF. RAF-kinase inhibitor protein (RKIP) downregulation in esophageal cancer and its metastases. Clin Exp Metastasis 2012;29(6):551-9
66. Kim HS, Lee SH, Won KY, et al. Expression of Raf-1 kinase inhibitory protein in carcinoma of the ampulla of Vater. Virchows Arch 2012;460:61-8
67. Martinho O, Faloppa CC, Neto CS, et al. Loss of RKIP expression during the carcinogenic evolution of endometrial cancer. J Clin Pathol 2012;65:122-8
68. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005;6:322-7
69. Al-Mulla F, Hagan S, Behbehani AI, et al. Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol 2006;24:5672-9
70. Minoo P, Zlobec I, Baker K, et al. Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am J Clin Pathol 2007;127:820-7
71. Zlobec I, Baker K, Minoo P, et al. Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression. Clin Cancer Res 2008;14:143-8
72. Doyle B, Hagan S, Al-Mulla F, et al. Raf Kinase Inhibitor Protein (RKIP), Lympho-Vascular Invasion and Peritoneal Invasion Can Be Used To Identify a High-Risk Group of Stage II Colorectal Cancer Patients. Mod Pathol 2012;25:159A-A
73. Kim HS, Park SJ, Lee KY, et al. Reduced Raf-1 kinase inhibitor protein expression predicts less favorable outcomes in patients with hepatic colorectal metastasis. Oncol Rep 2012;28:161-71
74. Koelzer V, Karamitopoulou E, Dawson H, et al. Geographic analysis of the protein expression of metastasis suppressor gene RKIP and its clinical relevance in colorectal cancer. Virchows Arch 2012; In press
75. Al-Mulla F, Bitar MS, Al-Maghrebi M, et al. Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3beta. Cancer Res 2011;71:1334-43
76. Zhu S, Mc Henry KT, Lane WS, Fenteany G. A chemical inhibitor reveals the role of Raf kinase inhibitor protein in cell migration. Chem Biol 2005;12:981-91
77. Shemon AN, Eves EM, Clark MC, et al. Raf Kinase inhibitory protein protects cells against locostatin-mediated inhibition of migration. PLoS One 2009;4:e6028
78. Shemon AN, Heil GL, Granovsky AE, et al. Characterization of the Raf kinase inhibitory protein (RKIP) binding pocket: NMR-based screening identifies small-molecule ligands. PLoS One 2010;5:e10479
79. al-Mulla F, Bitar MS, Taqi Z, et al. RAF kinase inhibitory protein (RKIP) modulates cell cycle kinetics and motility. Mol Biosyst 2011;7:928-41
80. Yeung KC, Rose DW, Dhillon AS, et al. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol 2001;21:7207-17
81. Beshir AB, Ren G, Magpusao AN, et al. Raf kinase inhibitor protein suppresses nuclear factor-kappaB-dependent cancer cell invasion through negative regulation of matrix metalloproteinase expression. Cancer Lett 2010;299:137-49
82. Stein U, Walther W, Arlt F, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 2009;15:59-67
83. Shirahata A, Fan W, Sakuraba K, et al. MACC 1 as a marker for vascular invasive hepatocellular carcinoma. Anticancer Res 2011;31:777-80
84. Shirahata A, Sakata M, Kitamura Y, et al. MACC 1 as a marker for peritoneal-disseminated gastric carcinoma. Anticancer Res 2010;30:3441-4
85. Shirahata A, Shinmura K, Kitamura Y, et al. MACC1 as a marker for advanced colorectal carcinoma. Anticancer Res 2010;30:2689-92
86. Galimi F, Torti D, Sassi F, et al. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations. Clin Cancer Res 2011;17:3146-56
87. Lang AH, Geller-Rhomberg S, Winder T, et al. A common variant of the MACC1 gene is significantly associated with overall survival in colorectal cancer patients. BMC Cancer 2012;12:20
88. Kawamura M, Saigusa S, Toiyama Y, et al. Correlation of MACC1 and MET expression in rectal cancer after neoadjuvant chemoradiotherapy. Anticancer Res 2012;32:1527-31
89. Nitsche U, Rosenberg R, Balmert A, et al. Integrative Marker Analysis Allows Risk Assessment for Metastasis in Stage II Colon Cancer. Ann Surg 2012;256:763-71
90. Neumann J, Horst D, Kriegl L, et al. A simple immunohistochemical algorithm predicts the risk of distant metastases in right-sided colon cancer. Histopathology 2012;60:416-26
91. Ghosh D, Yu H, Tan XF, et al. Identification of key players for colorectal cancer metastasis by iTRAQ quantitative proteomics profiling of isogenic SW480 and SW620 cell lines. J Proteome Res 2011;10:4373-87
92. Zhao L, Liu L, Wang S, et al. Differential proteomic analysis of human colorectal carcinoma cell lines metastasis-associated proteins. J Cancer Res Clin Oncol 2007;133:771-82
93. Biglarian A, Bakhshi E, Gohari MR, Khodabakhshi R. Artificial neural network for prediction of distant metastasis in colorectal cancer. Asian Pac J Cancer Prev 2012;13:927-30
94. Ki DH, Jeung HC, Park CH, et al. Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer 2007;121:2005-12
95. Koehler A, Bataille F, Schmid C, et al. Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage. J Pathol 2004;204:65-74
96. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010;28:1254-61
97. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138:2073-87; e2073
98. Karamitopoulou E, Zlobec I, Koelzer V, et al. Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol 2012; Epub ahead of print
99. Qu JH, Chang XJ, Lu YY, et al. Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2012;18:2995-3003